250 related articles for article (PubMed ID: 35023132)
1. Biomarkers and Precision Medicine in Alzheimer's Disease.
Sagar R; Pathak P; Pandur B; Kim SJ; Li J; Mahairaki V
Adv Exp Med Biol; 2021; 1339():403-408. PubMed ID: 35023132
[TBL] [Abstract][Full Text] [Related]
2. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
3. Precision pharmacology for Alzheimer's disease.
Hampel H; Vergallo A; Aguilar LF; Benda N; Broich K; Cuello AC; Cummings J; Dubois B; Federoff HJ; Fiandaca M; Genthon R; Haberkamp M; Karran E; Mapstone M; Perry G; Schneider LS; Welikovitch LA; Woodcock J; Baldacci F; Lista S;
Pharmacol Res; 2018 Apr; 130():331-365. PubMed ID: 29458203
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?
Mullane K; Williams M
Biochem Pharmacol; 2020 Jul; 177():113945. PubMed ID: 32247851
[TBL] [Abstract][Full Text] [Related]
5. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
[TBL] [Abstract][Full Text] [Related]
6. Early detection and personalized medicine: Future strategies against Alzheimer's disease.
Di Meco A; Vassar R
Prog Mol Biol Transl Sci; 2021; 177():157-173. PubMed ID: 33453940
[TBL] [Abstract][Full Text] [Related]
7. Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease.
Alexopoulos P; Werle L; Roesler J; Thierjung N; Gleixner LS; Yakushev I; Laskaris N; Wagenpfeil S; Gourzis P; Kurz A; Perneczky R;
Alzheimers Res Ther; 2016 Dec; 8(1):51. PubMed ID: 27931251
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer's Targeted Treatments: Focus on Amyloid and Inflammation.
Iwatsubo T; Irizarry MC; Lewcock JW; Carrillo MC
J Neurosci; 2023 Nov; 43(47):7894-7898. PubMed ID: 37968119
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
[TBL] [Abstract][Full Text] [Related]
10. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
[TBL] [Abstract][Full Text] [Related]
11. [Alzheimer's disease - the most common cause of dementia].
Bogdanovic N; Hansson O; Zetterberg H; Basun H; Ingelsson M; Lannfelt L; Blennow K
Lakartidningen; 2020 Mar; 117():. PubMed ID: 32154904
[TBL] [Abstract][Full Text] [Related]
12. Nanotechnology in Personalized Medicine: A Promising Tool for Alzheimer's Disease Treatment.
De Matteis L; Martín-Rapún R; de la Fuente JM
Curr Med Chem; 2018; 25(35):4602-4615. PubMed ID: 29022501
[TBL] [Abstract][Full Text] [Related]
13. Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.
Hampel H; Mitchell A; Blennow K; Frank RA; Brettschneider S; Weller L; Möller HJ
J Neural Transm (Vienna); 2004 Mar; 111(3):247-72. PubMed ID: 14991453
[TBL] [Abstract][Full Text] [Related]
14. miRNAs as Therapeutic Tools in Alzheimer's Disease.
Lee CY; Ryu IS; Ryu JH; Cho HJ
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884818
[TBL] [Abstract][Full Text] [Related]
15. Progression of Alzheimer's disease, tau propagation, and its modifiable risk factors.
Takeda S
Neurosci Res; 2019 Apr; 141():36-42. PubMed ID: 30120962
[TBL] [Abstract][Full Text] [Related]
16. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
[TBL] [Abstract][Full Text] [Related]
17. Cognitive Dispersion Is Not Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Results from the European Prevention of Alzheimer's Dementia (EPAD) v500.0 Cohort.
Watermeyer T; Marroig A; Ritchie CW; Ritchie K; Blennow K; Muniz-Terrera G;
J Alzheimers Dis; 2020; 78(1):185-194. PubMed ID: 32955462
[TBL] [Abstract][Full Text] [Related]
18. Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition.
Tan CH; Fan CC; Mormino EC; Sugrue LP; Broce IJ; Hess CP; Dillon WP; Bonham LW; Yokoyama JS; Karch CM; Brewer JB; Rabinovici GD; Miller BL; Schellenberg GD; Kauppi K; Feldman HA; Holland D; McEvoy LK; Hyman BT; Bennett DA; Andreassen OA; Dale AM; Desikan RS;
Acta Neuropathol; 2018 Jan; 135(1):85-93. PubMed ID: 29177679
[TBL] [Abstract][Full Text] [Related]
19. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
[TBL] [Abstract][Full Text] [Related]
20. Emerging amyloid and tau targeting treatments for Alzheimer's disease.
Khan A; Corbett A; Ballard C
Expert Rev Neurother; 2017 Jul; 17(7):697-711. PubMed ID: 28490214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
